‘Conscious consumer’ demand is propelling cosmeceuticals industry, experts tell CPHI Discover audience
Upstream raw materials suppliers seen as the main source of innovation in a growing industry driven by demand for more natural ingredients manufactured in clean, sustainable way
Savvy consumers in search of more sustainable and cleaner beauty products that contain new natural ingredients are driving growing demand in the cosmeceuticals sector, according to experts speaking at CPHI Discover on Thursday.
In the webinar, Formulating Natural Ingredients for Cosmeceuticals, Akshay Talati, Vice President - Research & Innovation at L'Oréal said that while natural cosmetic ingredients have been in the market for over 25 years, it is only during the last five to six years that consumers have been moving over to the category of so-called ‘conscious beauty’ where sustainability concerns take precedence.
“50% of the products in cosmetics launched today have some kind of natural claim, which could be related to packaging, sustainability, ingredients, marketing etc.,” he told the audience. “This trend is going to continue; people are looking more for conscious beauty which is giving back to the planet and bringing back the whole concept of skin being the future of health and they are looking for products and ingredients that perform and they are coming back to naturals.”
He added that ‘star’ ingredients such as retinol, vitamin C, salicylic acid, hyaluronic acid and peptides are still powering most of the cosmetics products in terms of performance as they did 25 years ago when he joined the industry.
“What has changed is that the percentages of use of these ingredients has increased and whereas 25 year ago we did have naturals, at the time they were used more in diluted liquid solutions and were more for storage purposes – people were looking for basic moisturisers and anti-aging ingredients,” he said. “Now consumers are demanding more when it comes to performance; they are pushing the envelope and going almost towards cosmeceutical drug territory. They are looking for 20% nicotinamide and 30% glycolic acid, and then to support these are new natural ingredients.”
Sylesh Venkataraman, Global Business Manager, Botanical Ingredients at Lubrizol Life Science- Beauty said that in his role identifying new extracts and molecules, “the perspective has changed.”
“The market is looking for natural ingredients obtained by a clean, sustainable way in an approach where you impact the circular economy,” he said. “What we do is understand the molecules that are present in nature, utilise a design approach that focuses on efficacy, and do a screening evaluation of extracts produced by a clean technology.”
He added that while previous methodologies involved hazardous solvents, based on consumer insights, “we are now changing it into using natural technologies.”
Talati said that he had recently conducted an online poll among likeminded professionals in cosmetics including researchers, formulators and brand makers and they identified raw material manufacturers as the main source of innovation in cosmeceuticals.
“Innovation in the cosmetics industry does starts upstream to downstream,” he said. “The raw materials manufacturers start the idea and bring the ingredient and then it’s up to the formulators and marketers on how to create the message from that ingredient to bring to the consumers.”
“Natural ingredients are more popular than ever and what is encouraging about this exciting trend is this focus on innovation, on validation and on how both as formulators and ingredients companies, we are really thinking about how we use botanicals to provide the benefits we want to provide to give a better product,” said the session chair, Pushpa Vijayaraghavan, Director & Practice Lead- Healthcare at Sathguru Management Consultants. “I think in the next decade, global traditional knowledge is actually going to power more and more innovation, combined with a sustainability focus.”
This webinar will be available on demand from 31 May. In the meantime, for details on how to register for this ongoing virtual event, head to the CPHI Discover website
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance